Results 141 to 150 of about 98,157 (333)

Identification of Histone Deacetylase Inhibitor Targeting Type I Interferon and B Cell Abnormalities in Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is characterized by increased Type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama, Hachiro Konaka, Yasuhiro Kato, Takayuki Shibahara, Chisato Nishizawa, Kohei Tsujimoto, JeongHoon Park, Eri Itotagawa, Tatsunori Jo, Masayuki Nishide, Sumiyuki Nishida, Yoshihito Shima, Masashi Narazaki, Wataru Aoki, Ken J Ishii, Hyota Takamatsu, Atsushi Kumanogoh   +16 more
wiley   +1 more source

MicroRNA-29 (miR-29); c-Myc (MYC); histone deacetylase 3 (HDAC3); enhancer of zeste homolog 2 (EZH2) [PDF]

, 2012

openalex   +1 more source

Supplementary Figure 2 from Histone Deacetylase Inhibitors Influence Chemotherapy Transport by Modulating Expression and Trafficking of a Common Polymorphic Variant of the ABCG2 Efflux Transporter

, 2023
Agnès Basseville, Akina Tamaki, Caterina Ieranò, Shana Y. Trostel, Yvona Ward, Robert W. Robey, Ramanujan S. Hegde, Susan E. Bates   +7 more
openalex   +1 more source

Possible therapeutic repositioning of valproic acid: From epileptic seizures to acute kidney injury

British Journal of Clinical Pharmacology, EarlyView.
Valproic acid, an anticonvulsant, may be repositioned to prevent acute kidney injury due to ischemia followed by reperfusion. It preserves renal functions, electrolyte homeostasis and active sodium transport in kidney tubules, and blocks the onset of hypertension.
Danilo Alves‐Bezerra, Luiza B. Negreiros, Amaury Pereira‐Acácio, Isadora G. Almeida, João P. M. Veloso‐Santos, Jarlene A. Lopes, Glória Costa‐Sarmento, Humberto Muzi‐Filho, Adalberto Vieyra   +8 more
wiley   +1 more source

Supplementary Methods from Histone Deacetylase Inhibitor Sodium Butyrate Enhances the Cell Killing Effect of Psoralen plus UVA by Attenuating Nucleotide Excision Repair

, 2023
Tatsushi Toyooka, Yuko Ibuki
openalex   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

ΔFosB Regulates Gene Expression and Cognitive Dysfunction in a Mouse Model of Alzheimer\u27s Disease. [PDF]

, 2017
Alzheimer\u27s disease (AD) is characterized by cognitive decline and 5- to 10-fold increased seizure incidence. How seizures contribute to cognitive decline in AD or other disorders is unclear.
Aschmies, Suzan, Ashok, Annie, Chin, Jeannie, Corbett, Brian F, Fu, Chia-Hsuan, Hazra, Anupam, Iascone, Daniel M, Nestler, Eric J, Petrof, Iraklis, Pyfer, Mark S, Stephens, Gabriel S, Tosi, Umberto, You, Jason C, Zhang, Xiaohong, Zhao, Lijuan   +14 more
core   +1 more source

Supplementary Figure 4 from Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling

, 2023
K. Ted Thurn, Scott Thomas, Paromita Raha, Ian Qureshi, Pamela N. Münster   +4 more
openalex   +1 more source

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, EarlyView.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

The Role of HDACs as Leukemia Therapy Targets using HDI

International Journal of Hematology-Oncology and Stem Cell Research, 2016
Histone deacetylases (HDACs) are the enzymes causing deacetylation of histone and non-histone substrates. Histone deacetylase inhibitors (HDIs) are a family of drugs eliminating the effect of HDACs in malignant cells via inhibition of HDACs.
Ahmad Ahmadzadeh, Elahe Khodadi, Mohammad Shahjahani, Jessika Bertacchini, Tina Vosoughi, Najmaldin Saki   +5 more
doaj